THE RELATIONSHIP BETWEEN GUT MICROBIOME ALTERATIONS AND HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS B PATIENTS: A CLINICAL AND MICROBIOLOGICAL STUDY FROM IRAQ

Ameer Najy Obeed

doi:10.61796/jmgcb.v2i12.1587

Authors

Ameer Najy Obeed
ameer.najy.obeed@uomus.edu.iq
Al-Mustaqbal University, Iraq

Vol. 2 No. 12 (2025): Journal of Medical Genetics and Clinical Biology

Articles

November 10, 2025

Downloads

VIEW ARTICLE

Abstract
How to Cite
Metrics
References
License

Objective: To investigate the relationship between gut microbiome composition and the development of HCC in Iraqi patients with chronic HBV infection. Method: A cross-sectional case-control study was conducted involving 150 participants divided into three groups: HBV with HCC (n=60), HBV without HCC (n=60), and healthy controls (n=30). Clinical, biochemical, and microbiome data (16S rRNA sequencing of fecal samples) were collected. Statistical analyses included ANOVA, chi-square, and Pearson correlation. Results: Patients with HCC exhibited significant dysbiosis, characterized by decreased microbial diversity (Shannon index: 2.8 ± 0.4) compared to HBV-only (3.6 ± 0.5) and controls (4.1 ± 0.3), p<0.001. Increased abundance of Bacteroides fragilis and Enterobacteriaceae correlated with higher AFP levels (r=0.63, p<0.001). Novelty: Gut microbiome alterations are associated with HCC development in chronic HBV patients. These findings suggest potential microbiome-based biomarkers for early detection and therapeutic strategies.

Obeed, A. N. (2025). THE RELATIONSHIP BETWEEN GUT MICROBIOME ALTERATIONS AND HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS B PATIENTS: A CLINICAL AND MICROBIOLOGICAL STUDY FROM IRAQ. Journal of Medical Genetics and Clinical Biology, 2(12), 639–642. https://doi.org/10.61796/jmgcb.v2i12.1587

Download Citation

World Health Organization, Global Hepatitis Report. Geneva: World Health Organization, 2023.

Q. Liang and others, “Gut microbiome and hepatocellular carcinoma: Mechanistic insights,” Liver Int., vol. 41, pp. 2550–2565, 2021.

X. Zhang and others, “Dysbiosis of gut microbiota in patients with HBV-related HCC,” Front. Cell. Infect. Microbiol., vol. 12, p. 834567, 2022.

Y. Wang and others, “Microbiome alterations and liver cancer progression,” J. Hepatol., vol. 73, pp. 1172–1183, 2020.

J. Chen and others, “Role of gut microbiota in chronic HBV infection and HCC,” Gut Microbes, vol. 13, no. 1, p. e1899053, 2021.

R. Al-Khafaji and others, “Gut microbiome profiling in Iraqi HBV patients: A pilot study,” Microb. Pathog., vol. 175, p. 105914, 2023.

M. S. Mohamed and N. A. Nassir, “Prevalence of urinary tract infection and associated factors among pregnant women attending the obstetric clinic of Baghdad Teaching Hospital, 2023--2024,” Iraqi J. Community Med., vol. 38, pp. 68–74, 2025.

K. F. Nassir et al., “The impact of clinical pharmacists’ intervention on the rational use of intravenous paracetamol vials in Baghdad Teaching Hospital: A case-control study,” Pharmacia, vol. 71, pp. 1–7, 2024, doi: 10.3897/pharmacia.71.e123654.

N. A. Abood, D. J. Kadhim, and R. J. Hussein, “Medication-related burden among Iraqi patients with ulcerative colitis: a cross-sectional study,” J. Med. Life, vol. 17, no. 8, pp. 800–805, 2024, doi: 10.25122/jml-2023-0342.

J. Ni et al., “Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma,” Front. Microbiol., vol. 10, p. 1458, 2019, doi: 10.3389/fmicb.2019.01458.

Y. Lapidot et al., “Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma,” mSystems, vol. 5, no. 3, pp. e00153-20, 2020, doi: 10.1128/mSystems.00153-20.

Y.-C. Peng, J.-X. Xu, C.-F. Zeng, X.-H. Zhao, L.-Q. Li, and L.-N. Qi, “Gut microbiome dysbiosis in patients with hepatitis B virus-related hepatocellular carcinoma after extended hepatectomy liver failure,” Ann. Transl. Med., vol. 10, no. 10, p. 549, 2022, doi: 10.21037/atm-22-1958.

Z. Ren et al., “Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma,” Gut, vol. 68, no. 6, pp. 1014–1023, 2019, doi: 10.1136/gutjnl-2017-315084.

F. R. Ponziani et al., “Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease,” Hepatology, vol. 69, no. 1, pp. 107–120, 2019, doi: 10.1002/hep.30036.

F. R. Ponziani et al., “Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease,” Hepatology, vol. 69, no. 1, pp. 107–120, 2019, doi: 10.1002/hep.30036.

P.-C. Lee et al., “Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma,” J. Immunother. Cancer, vol. 10, no. 6, p. e004779, 2022, doi: 10.1136/jitc-2022-004779.